Development of Covariate Adjustment Methods to Improve Efficiency of Randomized Clinical Trials for human immunodeficiency virus infected Patients

Drug development requires significant time and financial resources. Despite the remarkable success in treating patients infected with the human immunodeficiency virus (HIV), which causes serious infectious diseases and cancer if left untreated, there remains a need for more effective, safer, and more convenient treatments. Efficient study methodologies that save time and money are essential.
One approach to enhance drug development efficiency is covariate adjustment. This analytical method is used in clinical studies. In typical drug development trials, patients are randomly assigned to either an experimental or a control treatment. Comparing the outcomes of these two groups provides a valid estimate of treatment effect. In HIV drug studies, researchers compare the proportions of patients with HIV levels below a certain threshold. However, covariate adjustment methods provide a more precise estimate of treatment effect than simple comparisons. By incorporating patient characteristics that predict study outcomes, we can reduce random error. Consequently, covariate adjustment reduces the required number of subjects and study duration.
In our study, we introduce a new covariate adjustment method for HIV drug trials, focusing on the proportion of patients achieving virus levels below a specific threshold. We apply this method to an existing HIV drug study and compare its results with those of simple group comparison and existing covariate adjustment methods. Ultimately, our research aims to improve the efficiency of HIV drug studies and enhance the quality of life for future patients living with HIV.